Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...

The MarketWatch News Department was not involved in the creation of this content. -- Presentation highlights novel TLR7/8 co-agonist in combination with pembrolizumab and chemotherapy in late-stage ...

Additional clinical-stage programs, including a Phase 2/3 trial in advanced melanoma, underscore momentum across the company’s oncology pipeline Eikon Therapeutics, Inc., a late-stage clinical ...

First safety-and-efficacy readout from selective PARP1 inhibitor EIK1003-001 New clinical trial collaboration and supply agreement with Merck First patient dosed in Phase 1/2 study of CNS-penetrant ...

(KRON) — A Bay Area biotech company that laid off dozens of people this week has blamed the job cuts on policies of the Trump administration. Eikon Therapeutics Inc. cut 55 jobs from its Millbrae ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The market for research ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. MEMPHIS, Tenn. — Every Tuesday, as part of ...

SDVI, a platform provider for cloud-native media supply chains, has integrated its Rally media supply chain management platform with the new EIKON-iQ intelligent integration gateway to enable full ...

Startup Eikon Therapeutics raised one of the biggest biotech rounds thus far in this young year. The Hayward, California-based drug startup closed on nearly $351 million in a Series D from the likes ...

Eikon Therapeutics, a company headed by the former Merck executive who steered the cancer drug Keytruda to FDA approval, has raised $350.7 million to support a pipeline that includes a lead drug ...

Eikon Therapeutics is no stranger to eye-popping funding rounds, and the cancer-focused biotech has continued this trend with a $350.7 million series D to fuel its various clinical trials.